Reuters logo
BRIEF-Abbvie granted priority review in Japan for its investigational regimen of Glecaprevir
March 14, 2017 / 12:26 PM / 9 months ago

BRIEF-Abbvie granted priority review in Japan for its investigational regimen of Glecaprevir

March 14 (Reuters) - Abbvie Inc

* Abbvie granted priority review in Japan for its investigational regimen of Glecaprevir/Pibrentasvir (G/P) for the treatment of all major genotypes of chronic hepatitis c

* Priority review follows EMA accelerated assessment and U.S. FDA priority review designations in December 2016 and January 2017 respectively Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below